{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T10:19:15Z","timestamp":1761733155251,"version":"build-2065373602"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001791","name":"Griffith University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001791","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is characterized by inflammation of small- to medium-sized blood vessels with ANCAs. Induction therapy has historically involved cyclophosphamide (CYC) and glucocorticoids (GCS), with rituximab (RTX) emerging as a preferred alternative. Studies addressed the efficacy of RTX in severe kidney diseases, showing results comparable to CYC. In severe diseases that are unsuitable for high-dose CYC, combined RTX and low-dose CYC demonstrate promising results. There is a recent trend to administer low-dose GCS to reduce infections and other complications. Recent trials have questioned the broader role of plasma exchange (PLEX), influencing guidelines\u2019 updates. Current indications for PLEX include severe kidney dysfunction, positive glomerular basement membrane antibody, and diffuse alveolar hemorrhage that requires oxygen support at presentation. Maintenance therapy options include azathioprine, RTX, and methotrexate. RTX's efficacy as a maintenance agent was demonstrated in trials. However, controversies in dosing frequency persist. The optimal duration of maintenance therapy remains debated, with guidelines suggesting 18\u201348\u00a0months. More recent studies proposed longer durations to reduce the risk of relapse, thus challenging existing guidelines. Complement involvement in AAV has been increasingly recognized. Studies show that complement 3 depositions in the glomeruli correlate with severe disease and complement inhibitors such as avacopan demonstrated efficacy in the management of AAV. Other complement inhibitors, such as eculizumab and vilobelimab, are being explored. In conclusion, AAV management has made significant advances, but controversies persist. Future research should refine therapeutic regimens and explore novel targeted treatments for personalized medicine in AAV.<\/jats:p>","DOI":"10.1007\/s10157-025-02693-w","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T08:44:32Z","timestamp":1747730672000},"page":"1515-1523","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutics controversies in antineutrophilic cytoplasmic antibody-associated vasculitis"],"prefix":"10.1007","volume":"29","author":[{"given":"Ken W. T.","family":"Chau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zaw","family":"Thet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Logan S.","family":"Gardner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tien K.","family":"Khoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2771-564X","authenticated-orcid":false,"given":"Alfred K.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dwarakanathan","family":"Ranganathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,20]]},"reference":[{"issue":"Suppl 1","key":"2693_CR1","doi-asserted-by":"publisher","first-page":"i14","DOI":"10.1093\/ndt\/gfv022","volume":"30","author":"RA Watts","year":"2015","unstructured":"Watts RA, Mahr A, Mohammad AJ, Gatenby P, Basu N, Flores-Suarez LF. Classification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Nephrol Dial Transplant. 2015;30(Suppl 1):i14-22. https:\/\/doi.org\/10.1093\/ndt\/gfv022.","journal-title":"Nephrol Dial Transplant"},{"issue":"25","key":"2693_CR2","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJM198806233182504","volume":"318","author":"RJ Falk","year":"1988","unstructured":"Falk RJ, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med. 1988;318(25):1651\u20137. https:\/\/doi.org\/10.1056\/NEJM198806233182504.","journal-title":"N Engl J Med"},{"issue":"6284","key":"2693_CR3","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/346520a0","volume":"346","author":"DE Jenne","year":"1990","unstructured":"Jenne DE, Tschopp J, Ludemann J, Utecht B, Gross WL. Wegener\u2019s autoantigen decoded. Nature. 1990;346(6284):520. https:\/\/doi.org\/10.1038\/346520a0.","journal-title":"Nature"},{"issue":"10","key":"2693_CR4","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/nrrheum.2016.123","volume":"12","author":"D Cornec","year":"2016","unstructured":"Cornec D, Cornec-Le Gall E, Fervenza FC, Specks U. ANCA-associated vasculitis - clinical utility of using ANCA specificity to classify patients. Nat Rev Rheumatol. 2016;12(10):570\u20139. https:\/\/doi.org\/10.1038\/nrrheum.2016.123.","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"2693_CR5","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"JH Stone","year":"2010","unstructured":"Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221\u201332. https:\/\/doi.org\/10.1056\/NEJMoa0909905.","journal-title":"N Engl J Med"},{"issue":"3","key":"2693_CR6","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa0909169","volume":"363","author":"RB Jones","year":"2010","unstructured":"Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363(3):211\u201320. https:\/\/doi.org\/10.1056\/NEJMoa0909169.","journal-title":"N Engl J Med"},{"issue":"3","key":"2693_CR7","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1016\/j.kint.2023.10.008","volume":"105","author":"J Floege","year":"2024","unstructured":"Floege J, Jayne DRW, Sanders J-SF, Tesar V, Rovin BH. KDIGO 2024 Clinical practice guideline for the management of Antineutrophil Cytoplasmic Antibody (ANCA)-associated vasculitis. Kidney Int. 2024;105(3):S71\u2013116. https:\/\/doi.org\/10.1016\/j.kint.2023.10.008.","journal-title":"Kidney Int"},{"issue":"2","key":"2693_CR8","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s40620-015-0208-y","volume":"29","author":"D Geetha","year":"2016","unstructured":"Geetha D, Hruskova Z, Segelmark M, Hogan J, Morgan MD, Cavero T, et al. Rituximab for treatment of severe renal disease in ANCA associated vasculitis. J Nephrol. 2016;29(2):195\u2013201. https:\/\/doi.org\/10.1007\/s40620-015-0208-y.","journal-title":"J Nephrol"},{"issue":"11","key":"2693_CR9","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1681\/ASN.2019111197","volume":"31","author":"M Casal Moura","year":"2020","unstructured":"Casal Moura M, Irazabal MV, Eirin A, Zand L, Sethi S, Borah BJ, et al. Efficacy of rituximab and plasma exchange in antineutrophil cytoplasmic antibody-associated vasculitis with severe kidney disease. J Am Soc Nephrol. 2020;31(11):2688\u2013704. https:\/\/doi.org\/10.1681\/ASN.2019111197.","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"2693_CR10","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.43799","volume":"5","author":"X Puechal","year":"2022","unstructured":"Puechal X, Iudici M, Perrodeau E, Bonnotte B, Lifermann F, Le Gallou T, et al. Rituximab vs cyclophosphamide induction therapy for patients with granulomatosis with polyangiitis. JAMA Netw Open. 2022;5(11): e2243799. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.43799.","journal-title":"JAMA Netw Open"},{"issue":"6","key":"2693_CR11","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1016\/j.kint.2021.08.025","volume":"100","author":"K Gulati","year":"2021","unstructured":"Gulati K, Edwards H, Prendecki M, Cairns TD, Condon M, Galliford J, et al. Combination treatment with rituximab, low-dose cyclophosphamide and plasma exchange for severe antineutrophil cytoplasmic antibody-associated vasculitis. Kidney Int. 2021;100(6):1316\u201324. https:\/\/doi.org\/10.1016\/j.kint.2021.08.025.","journal-title":"Kidney Int"},{"issue":"2","key":"2693_CR12","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.ekir.2017.11.004","volume":"3","author":"FB Cortazar","year":"2018","unstructured":"Cortazar FB, Muhsin SA, Pendergraft WF 3rd, Wallace ZS, Dunbar C, Laliberte K, et al. Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis. Kidney Int Rep. 2018;3(2):394\u2013402. https:\/\/doi.org\/10.1016\/j.ekir.2017.11.004.","journal-title":"Kidney Int Rep"},{"issue":"3","key":"2693_CR13","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1136\/annrheumdis-2018-214245","volume":"78","author":"RB Jones","year":"2019","unstructured":"Jones RB, Hiemstra TF, Ballarin J, Blockmans DE, Brogan P, Bruchfeld A, et al. Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial. Ann Rheum Dis. 2019;78(3):399\u2013405. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214245.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"2693_CR14","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.drudis.2016.06.009","volume":"21","author":"V Reddy","year":"2016","unstructured":"Reddy V, Dahal LN, Cragg MS, Leandro M. Optimising B-cell depletion in autoimmune disease: is obinutuzumab the answer? Drug Discov Today. 2016;21(8):1330\u20138. https:\/\/doi.org\/10.1016\/j.drudis.2016.06.009.","journal-title":"Drug Discov Today"},{"issue":"1","key":"2693_CR15","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","volume":"81","author":"RA Furie","year":"2022","unstructured":"Furie RA, Aroca G, Cascino MD, Garg JP, Rovin BH, Alvarez A, et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2022;81(1):100\u20137. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220920.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"2693_CR16","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.1093\/rheumatology\/keab916","volume":"61","author":"NA Amudala","year":"2022","unstructured":"Amudala NA, Boukhlal S, Sheridan B, Langford CA, Geara A, Merkel PA, et al. Obinutuzumab as treatment for ANCA-associated vasculitis. Rheumatology (Oxford). 2022;61(9):3814\u20137. https:\/\/doi.org\/10.1093\/rheumatology\/keab916.","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"2693_CR17","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1056\/NEJMoa1803537","volume":"382","author":"M Walsh","year":"2020","unstructured":"Walsh M, Merkel PA, Peh CA, Szpirt WM, Puechal X, Fujimoto S, et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med. 2020;382(7):622\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1803537.","journal-title":"N Engl J Med"},{"issue":"7","key":"2693_CR18","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa2023386","volume":"384","author":"DRW Jayne","year":"2021","unstructured":"Jayne DRW, Merkel PA, Schall TJ, Bekker P, Group AS. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med. 2021;384(7):599\u2013609. https:\/\/doi.org\/10.1056\/NEJMoa2023386.","journal-title":"N Engl J Med"},{"issue":"3","key":"2693_CR19","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1093\/rheumatology\/keu366","volume":"54","author":"J Robson","year":"2015","unstructured":"Robson J, Doll H, Suppiah R, Flossmann O, Harper L, Hoglund P, et al. Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials. Rheumatology (Oxford). 2015;54(3):471\u201381. https:\/\/doi.org\/10.1093\/rheumatology\/keu366.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"2693_CR20","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1093\/rheumatology\/kez388","volume":"59","author":"D McGovern","year":"2020","unstructured":"McGovern D, Williams SP, Parsons K, Farrah TE, Gallacher PJ, Miller-Hodges E, et al. Long-term outcomes in elderly patients with ANCA-associated vasculitis. Rheumatology (Oxford). 2020;59(5):1076\u201383. https:\/\/doi.org\/10.1093\/rheumatology\/kez388.","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"2693_CR21","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s41581-020-0269-6","volume":"16","author":"A Morris","year":"2020","unstructured":"Morris A, Geetha D. PEXIVAS challenges current ANCA-associated vasculitis therapy. Nat Rev Nephrol. 2020;16(7):373\u20134. https:\/\/doi.org\/10.1038\/s41581-020-0269-6.","journal-title":"Nat Rev Nephrol"},{"issue":"4","key":"2693_CR22","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/ki.1991.272","volume":"40","author":"CD Pusey","year":"1991","unstructured":"Pusey CD, Rees AJ, Evans DJ, Peters DK, Lockwood CM. Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int. 1991;40(4):757\u201363. https:\/\/doi.org\/10.1038\/ki.1991.272.","journal-title":"Kidney Int"},{"issue":"7","key":"2693_CR23","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1681\/ASN.2007010090","volume":"18","author":"DR Jayne","year":"2007","unstructured":"Jayne DR, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007;18(7):2180\u20138. https:\/\/doi.org\/10.1681\/ASN.2007010090.","journal-title":"J Am Soc Nephrol"},{"key":"2693_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-064604","volume":"376","author":"M Walsh","year":"2022","unstructured":"Walsh M, Collister D, Zeng L, Merkel PA, Pusey CD, Guyatt G, et al. The effects of plasma exchange in patients with ANCA-associated vasculitis: an updated systematic review and meta-analysis. BMJ. 2022;376: e064604. https:\/\/doi.org\/10.1136\/bmj-2021-064604.","journal-title":"BMJ"},{"key":"2693_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223764","author":"B Hellmich","year":"2023","unstructured":"Hellmich B, Sanchez-Alamo B, Schirmer JH, Berti A, Blockmans D, Cid MC, et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2023. https:\/\/doi.org\/10.1136\/ard-2022-223764.","journal-title":"Ann Rheum Dis"},{"key":"2693_CR26","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.rmcr.2018.09.016","volume":"25","author":"K Uto","year":"2018","unstructured":"Uto K, Yanagi S, Tsubouchi H, Matsumoto N, Nakazato M. Successful treatment of steroid-refractory double-positive ANCA and anti-GBM disease with a combination of plasma exchange and immunosuppression: a case report and literature review. Respir Med Case Rep. 2018;25:242\u20136. https:\/\/doi.org\/10.1016\/j.rmcr.2018.09.016.","journal-title":"Respir Med Case Rep"},{"issue":"3","key":"2693_CR27","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.kint.2017.03.014","volume":"92","author":"SP McAdoo","year":"2017","unstructured":"McAdoo SP, Tanna A, Hruskova Z, Holm L, Weiner M, Arulkumaran N, et al. Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients. Kidney Int. 2017;92(3):693\u2013702. https:\/\/doi.org\/10.1016\/j.kint.2017.03.014.","journal-title":"Kidney Int"},{"issue":"6","key":"2693_CR28","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1053\/j.ajkd.2003.08.015","volume":"42","author":"PJ Klemmer","year":"2003","unstructured":"Klemmer PJ, Chalermskulrat W, Reif MS, Hogan SL, Henke DC, Falk RJ. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis. 2003;42(6):1149\u201353. https:\/\/doi.org\/10.1053\/j.ajkd.2003.08.015.","journal-title":"Am J Kidney Dis"},{"issue":"26","key":"2693_CR29","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1056\/NEJMoa0802311","volume":"359","author":"C Pagnoux","year":"2008","unstructured":"Pagnoux C, Mahr A, Hamidou MA, Boffa JJ, Ruivard M, Ducroix JP, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med. 2008;359(26):2790\u2013803. https:\/\/doi.org\/10.1056\/NEJMoa0802311.","journal-title":"N Engl J Med"},{"issue":"3","key":"2693_CR30","doi-asserted-by":"publisher","first-page":"445","DOI":"10.2215\/CJN.06010809","volume":"5","author":"F Silva","year":"2010","unstructured":"Silva F, Specks U, Kalra S, Hogan MC, Leung N, Sethi S, et al. Mycophenolate mofetil for induction and maintenance of remission in microscopic polyangiitis with mild to moderate renal involvement\u2013a prospective, open-label pilot trial. Clin J Am Soc Nephrol. 2010;5(3):445\u201353. https:\/\/doi.org\/10.2215\/CJN.06010809.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"21","key":"2693_CR31","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1001\/jama.2010.1658","volume":"304","author":"TF Hiemstra","year":"2010","unstructured":"Hiemstra TF, Walsh M, Mahr A, Savage CO, de Groot K, Harper L, et al. Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA. 2010;304(21):2381\u20138. https:\/\/doi.org\/10.1001\/jama.2010.1658.","journal-title":"JAMA"},{"issue":"19","key":"2693_CR32","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","volume":"371","author":"L Guillevin","year":"2014","unstructured":"Guillevin L, Pagnoux C, Karras A, Khouatra C, Aumaitre O, Cohen P, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371(19):1771\u201380. https:\/\/doi.org\/10.1056\/NEJMoa1404231.","journal-title":"N Engl J Med"},{"issue":"7","key":"2693_CR33","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1136\/ard-2022-223559","volume":"82","author":"RM Smith","year":"2023","unstructured":"Smith RM, Jones RB, Specks U, Bond S, Nodale M, Al-Jayyousi R, et al. Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial. Ann Rheum Dis. 2023;82(7):937\u201344. https:\/\/doi.org\/10.1136\/ard-2022-223559.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"2693_CR34","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1136\/annrheumdis-2017-212878","volume":"77","author":"P Charles","year":"2018","unstructured":"Charles P, Terrier B, Perrodeau E, Cohen P, Faguer S, Huart A, et al. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis. 2018;77(8):1143\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212878.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"2693_CR35","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1002\/art.40802","volume":"71","author":"D Jayne","year":"2019","unstructured":"Jayne D, Blockmans D, Luqmani R, Moiseev S, Ji B, Green Y, et al. Efficacy and safety of belimumab and azathioprine for maintenance of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled study. Arthritis Rheumatol. 2019;71(6):952\u201363. https:\/\/doi.org\/10.1002\/art.40802.","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"2693_CR36","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1136\/annrheumdis-2017-211123","volume":"76","author":"A Karras","year":"2017","unstructured":"Karras A, Pagnoux C, Haubitz M, Groot K, Puechal X, Tervaert JWC, et al. Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. Ann Rheum Dis. 2017;76(10):1662\u20138. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211123.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"2693_CR37","doi-asserted-by":"publisher","first-page":"179","DOI":"10.7326\/M19-3827","volume":"173","author":"P Charles","year":"2020","unstructured":"Charles P, Perrodeau E, Samson M, Bonnotte B, Neel A, Agard C, et al. Long-term rituximab use to maintain remission of antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2020;173(3):179\u201387. https:\/\/doi.org\/10.7326\/M19-3827.","journal-title":"Ann Intern Med"},{"issue":"2","key":"2693_CR38","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1136\/ard-2023-224623","volume":"83","author":"F Delestre","year":"2024","unstructured":"Delestre F, Charles P, Karras A, Pagnoux C, Neel A, Cohen P, et al. Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials. Ann Rheum Dis. 2024;83(2):233\u201341. https:\/\/doi.org\/10.1136\/ard-2023-224623.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"2693_CR39","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1002\/art.41773","volume":"73","author":"SA Chung","year":"2021","unstructured":"Chung SA, Langford CA, Maz M, Abril A, Gorelik M, Guyatt G, et al. 2021 American College of Rheumatology\/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol. 2021;73(8):1366\u201383. https:\/\/doi.org\/10.1002\/art.41773.","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"2693_CR40","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1111\/j.1523-1755.2004.00632.x","volume":"65","author":"M Haas","year":"2004","unstructured":"Haas M, Eustace JA. Immune complex deposits in ANCA-associated crescentic glomerulonephritis: a study of 126 cases. Kidney Int. 2004;65(6):2145\u201352. https:\/\/doi.org\/10.1111\/j.1523-1755.2004.00632.x.","journal-title":"Kidney Int"},{"issue":"4","key":"2693_CR41","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1093\/ndt\/gfn586","volume":"24","author":"M Chen","year":"2009","unstructured":"Chen M, Xing GQ, Yu F, Liu G, Zhao MH. Complement deposition in renal histopathology of patients with ANCA-associated pauci-immune glomerulonephritis. Nephrol Dial Transplant. 2009;24(4):1247\u201352. https:\/\/doi.org\/10.1093\/ndt\/gfn586.","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"2693_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158871","volume":"11","author":"JF Augusto","year":"2016","unstructured":"Augusto JF, Langs V, Demiselle J, Lavigne C, Brilland B, Duveau A, et al. Low serum complement C3 levels at diagnosis of renal ANCA-associated vasculitis is associated with poor prognosis. PLoS ONE. 2016;11(7): e0158871. https:\/\/doi.org\/10.1371\/journal.pone.0158871.","journal-title":"PLoS ONE"},{"issue":"1","key":"2693_CR43","doi-asserted-by":"publisher","first-page":"52","DOI":"10.2353\/ajpath.2007.060573","volume":"170","author":"H Xiao","year":"2007","unstructured":"Xiao H, Schreiber A, Heeringa P, Falk RJ, Jennette JC. Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol. 2007;170(1):52\u201364. https:\/\/doi.org\/10.2353\/ajpath.2007.060573.","journal-title":"Am J Pathol"},{"issue":"2","key":"2693_CR44","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1681\/ASN.2013020143","volume":"25","author":"H Xiao","year":"2014","unstructured":"Xiao H, Dairaghi DJ, Powers JP, Ertl LS, Baumgart T, Wang Y, et al. C5a receptor (CD88) blockade protects against MPO-ANCA GN. J Am Soc Nephrol. 2014;25(2):225\u201331. https:\/\/doi.org\/10.1681\/ASN.2013020143.","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"2693_CR45","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1681\/ASN.2016111179","volume":"28","author":"DRW Jayne","year":"2017","unstructured":"Jayne DRW, Bruchfeld AN, Harper L, Schaier M, Venning MC, Hamilton P, et al. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J Am Soc Nephrol. 2017;28(9):2756\u201367. https:\/\/doi.org\/10.1681\/ASN.2016111179.","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"2693_CR46","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1002\/acr2.11185","volume":"2","author":"PA Merkel","year":"2020","unstructured":"Merkel PA, Niles J, Jimenez R, Spiera RF, Rovin BH, Bomback A, et al. Adjunctive treatment with avacopan, an oral c5a receptor inhibitor, in patients with antineutrophil cytoplasmic antibody-associated vasculitis. ACR Open Rheumatol. 2020;2(11):662\u201371. https:\/\/doi.org\/10.1002\/acr2.11185.","journal-title":"ACR Open Rheumatol"},{"issue":"6","key":"2693_CR47","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s11739-017-1636-6","volume":"12","author":"L Manenti","year":"2017","unstructured":"Manenti L, Urban ML, Maritati F, Galetti M, Vaglio A. Complement blockade in ANCA-associated vasculitis: an index case, current concepts and future perspectives. Intern Emerg Med. 2017;12(6):727\u201331. https:\/\/doi.org\/10.1007\/s11739-017-1636-6.","journal-title":"Intern Emerg Med"},{"issue":"12","key":"2693_CR48","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1093\/rheumatology\/kez190","volume":"58","author":"D Ribes","year":"2019","unstructured":"Ribes D, Belliere J, Piedrafita A, Faguer S. Glucocorticoid-free induction regimen in severe ANCA-associated vasculitis using a combination of rituximab and eculizumab. Rheumatology (Oxford). 2019;58(12):2335\u20137. https:\/\/doi.org\/10.1093\/rheumatology\/kez190.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"2693_CR49","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1093\/mrcr\/rxac029","volume":"6","author":"F Kitamura","year":"2022","unstructured":"Kitamura F, Yamaguchi M, Nishimura M, Katsuno T, Ito M, Sugiyama H, et al. Anti-neutrophil cytoplasmic antibody-associated vasculitis complicated by thrombotic microangiopathy with posterior reversible encephalopathy syndrome successfully treated with eculizumab: a case report. Mod Rheumatol Case Rep. 2022;6(2):254\u20139. https:\/\/doi.org\/10.1093\/mrcr\/rxac029.","journal-title":"Mod Rheumatol Case Rep"},{"key":"2693_CR50","unstructured":"Merkel P HB, Pfaff A, M\u00fcller C, Startseva E, Jayne D. A randomized, double-blind, phase II study of glucocorticoid replacement by vilobelimab, an anti-C5a monoclonal antibody, in ANCA-associated vasculitis [abstract]. Arthritis Rheumatol. 2022;74(suppl 9)."}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-025-02693-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-025-02693-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-025-02693-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:33:54Z","timestamp":1761708834000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-025-02693-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,20]]},"references-count":50,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["2693"],"URL":"https:\/\/doi.org\/10.1007\/s10157-025-02693-w","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"type":"print","value":"1342-1751"},{"type":"electronic","value":"1437-7799"}],"subject":[],"published":{"date-parts":[[2025,5,20]]},"assertion":[{"value":"8 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known conflicts of interest related to the research presented in this literature review, including any financial interests, personal relationships, or professional affiliations with organizations that could be perceived as influencing the interpretation or presentation of the findings.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This is a narrative literature review article which itself does not involve direct research with human participants and\/or animals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"This review article incorporates data from previously published studies, all of which were conducted with informed consent from participants according to ethical guidelines established by the respective institutions. The authors have ensured that all cited studies did not include identifiable personal information.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}